Somatic mutation screening should become a new standard for the diagnosis of NF2-,
LTZTR1-, SMARCB1-and 22q-schwannomatosis to discriminate those conditions …

Background: Vestibular schwannoma (VS) is a benign tumor of the eighth cranial nerve
formed from neoplastic Schwann cells. Although VS can cause a variety of symptoms …

Simple Summary In this study, we explored the use of bevacizumab as a treatment for NF2-
related schwannomatosis, a condition characterized by the development of schwannomas …

Purpose The evidence for treating patients with neurofibromatosis 2-related vestibular
schwannoma (VS-NF2) using hypofractionated stereotactic radiation therapy (HSRT) is …

Objectives To determine the natural history of hearing loss and tumor volume in patients with
untreated neurofibromatosis type 2 (NF2)-related schwannomatosis. Moreover, we …

Objectives To determine the long‐term control rates and hearing outcomes for growing
vestibular schwannoma in NF2‐related schwannomatosis (NF2) treated with stereotactic …

Objective The objective of this study was to explore serum microRNA (miRNA) profile
characteristic of patients with neurofibromatosis type 2 (NF2), including both sporadic and …

Objective A lack of understanding of the clinical course of neurofibromatosis type 2 (NF2)-
associated vestibular schwannoma (VS) often complicates the decision-making in terms of …

Simple Summary The management of vestibular schwannomas in neurofibromatosis type 2-
related schwannomatosis (NF2) is complex. Current treatment strategies include active …

Background Trigeminal schwannoma is an uncommon tumor in pediatric patients. Several
surgical approaches have been described in the literature. Methods The case of an 11-year …